Revance Therapeutics Inc (NASDAQ:RVNC) CEO L Daniel Browne sold 6,452 shares of the firm’s stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $31.64, for a total value of $204,141.28. Following the transaction, the chief executive officer now owns 130,208 shares in the company, valued at $4,119,781.12. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
L Daniel Browne also recently made the following trade(s):
- On Wednesday, March 7th, L Daniel Browne sold 27,283 shares of Revance Therapeutics stock. The stock was sold at an average price of $31.43, for a total value of $857,504.69.
Shares of Revance Therapeutics stock opened at $31.00 on Monday. Revance Therapeutics Inc has a fifty-two week low of $18.42 and a fifty-two week high of $37.45.
Revance Therapeutics (NASDAQ:RVNC) last released its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.99) by ($0.15). The firm had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.09 million. Revance Therapeutics had a negative net margin of 46,025.57% and a negative return on equity of 64.40%. The company’s revenue for the quarter was down 50.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.95) EPS. sell-side analysts predict that Revance Therapeutics Inc will post -3.64 EPS for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in shares of Revance Therapeutics in the 3rd quarter valued at approximately $144,000. Cowen Inc. bought a new position in Revance Therapeutics during the 4th quarter valued at approximately $225,000. Teacher Retirement System of Texas bought a new position in Revance Therapeutics during the 4th quarter valued at approximately $255,000. Voya Investment Management LLC bought a new position in Revance Therapeutics during the 2nd quarter valued at approximately $274,000. Finally, Quinn Opportunity Partners LLC bought a new position in Revance Therapeutics during the 4th quarter valued at approximately $325,000. Institutional investors own 95.14% of the company’s stock.
Several research firms recently issued reports on RVNC. Piper Jaffray Companies set a $48.00 price target on Revance Therapeutics and gave the stock a “buy” rating in a research report on Thursday, March 1st. Barclays started coverage on Revance Therapeutics in a report on Monday, November 27th. They issued an “overweight” rating and a $31.00 price objective for the company. Goldman Sachs started coverage on Revance Therapeutics in a report on Monday, March 5th. They issued a “buy” rating and a $60.00 price objective for the company. William Blair reiterated an “outperform” rating on shares of Revance Therapeutics in a report on Thursday, March 1st. Finally, Zacks Investment Research upgraded Revance Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 6th. One analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $45.45.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.